Download PDF
Nuklearmedizin 2013; 52(05): N58-N59
DOI: 10.1055/s-0038-1625751
Case report
Schattauer GmbH

Pre- and intratherapeutical ibritumomab tiuxetan Zevalin® dosimetry in childhood

C. Happel
1   Department of Nuclear Medicine, University Medical Centre Frankfurt
,
J. Diener
1   Department of Nuclear Medicine, University Medical Centre Frankfurt
,
W. T. Kranert
1   Department of Nuclear Medicine, University Medical Centre Frankfurt
,
B. Bockisch
1   Department of Nuclear Medicine, University Medical Centre Frankfurt
,
J. Pinkert
2   Bayer Vital GmbH, Leverkusen, Germany
,
F. Grünwald
1   Department of Nuclear Medicine, University Medical Centre Frankfurt
› Author Affiliations
Further Information

Publication History

received: 26 February 2013

accepted in revised form: 14 May 2013

Publication Date:
12 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Cooney-Qualter E, Krailo M, Angiolillo A. et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma. Clin Cancer Res 2007; 13: 5652s-5660s.
    CrossrefPubMedGoogle Scholar
  • 2 Fischer M, Grünwald F, Knapp WH. et al. Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin’s lymphoma. Nuklearmedizin 2009; 48: 215-220.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Grgic A, Nestle U, Scheidhauer K. et al. Retrospective web-based multicenter evaluation of 18F-FDGPET and CT derived predictive factors. Nuklearmedizin 2011; 50: 39-47.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Lassmann M, Chiesa C, Flux G. et al. EANM Dosimetry Committee guidance document. Eur J Nucl Med Mol Imaging 2011; 38: 192-200.
    CrossrefPubMedGoogle Scholar
  • 5 Tennvall J, Fischer M, Bischof Delaloye A. et al. EANM procedure guideline of radio-immunotherapy for B-cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan (Zevalin®). Eur J Nucl Med Mol Imaging 2007; 34: 616-622.
    CrossrefPubMedGoogle Scholar